CY1112330T1 - Πρωτεϊνες συνδεσης gag - Google Patents
Πρωτεϊνες συνδεσης gagInfo
- Publication number
- CY1112330T1 CY1112330T1 CY20111100904T CY111100904T CY1112330T1 CY 1112330 T1 CY1112330 T1 CY 1112330T1 CY 20111100904 T CY20111100904 T CY 20111100904T CY 111100904 T CY111100904 T CY 111100904T CY 1112330 T1 CY1112330 T1 CY 1112330T1
- Authority
- CY
- Cyprus
- Prior art keywords
- site
- gag binding
- proteins gag
- protein
- gag
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Παρέχεται μέθοδος για εισαγωγή μιας θέσης σύνδεσης GAG σε μία πρωτεΐνη που περιλαμβάνει τα στάδια: -πιστοποίησης μιας περιοχής σε μία πρωτεΐνη η οποία δεν είναι βασική για διατήρηση της δομής -εισαγωγή τουλάχιστον ενός βασικού αμινοξέος εντός της εν λόγω θέσης ή/και απαλοιφής τουλάχιστον ενός ογκώδους ή/και όξινου αμινοξέος στην εν λόγω θέση όπου η εν λόγω θέσης σύνδεσης GAG έχει συνάφεια σύνδεσης GAG Kd≤10 μΜ, κατά προτίμηση ≤1 μΜ, ακόμη προτιμότερα ≤0,1 μΜ, καθώς επίσης τροποποιημένες πρωτεΐνες σύνδεσης GAG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0195203A AT412785B (de) | 2003-12-04 | 2003-12-04 | Gag-bindungsproteine |
| EP04801190A EP1689775B1 (en) | 2003-12-04 | 2004-12-02 | GAG binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112330T1 true CY1112330T1 (el) | 2015-12-09 |
Family
ID=33494536
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101039T CY1109480T1 (el) | 2003-12-04 | 2009-10-08 | ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag |
| CY20111100904T CY1112330T1 (el) | 2003-12-04 | 2011-09-16 | Πρωτεϊνες συνδεσης gag |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101039T CY1109480T1 (el) | 2003-12-04 | 2009-10-08 | ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7585937B2 (el) |
| EP (5) | EP2311866A1 (el) |
| JP (3) | JP4980721B2 (el) |
| KR (2) | KR101188785B1 (el) |
| CN (1) | CN1890264B (el) |
| AT (3) | AT412785B (el) |
| AU (1) | AU2004295104B2 (el) |
| BR (1) | BRPI0416544A (el) |
| CA (1) | CA2546789A1 (el) |
| CY (2) | CY1109480T1 (el) |
| DE (1) | DE602004022595D1 (el) |
| DK (2) | DK1689775T3 (el) |
| ES (2) | ES2330362T3 (el) |
| IL (1) | IL175565A0 (el) |
| NZ (1) | NZ547612A (el) |
| PL (2) | PL1752470T3 (el) |
| PT (2) | PT1752470E (el) |
| SG (1) | SG149000A1 (el) |
| SI (2) | SI1689775T1 (el) |
| WO (1) | WO2005054285A1 (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| AU2006291990B2 (en) | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| CN100366637C (zh) * | 2005-11-17 | 2008-02-06 | 中国人民解放军第四军医大学 | 人白细胞介素8拮抗蛋白及其制备方法 |
| US9422356B2 (en) * | 2006-01-31 | 2016-08-23 | Republic Of Korea (Republic Of National Fisheries Research And Development Institute) | Artificial signal peptide for expressing an insoluble protein as a soluble active form |
| DK1994155T4 (da) | 2006-02-13 | 2022-07-25 | Daiichi Sankyo Co Ltd | Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| EP1894571A1 (en) * | 2006-08-29 | 2008-03-05 | Protaffin Biotechnologie AG | Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection |
| US20100075918A1 (en) * | 2006-12-08 | 2010-03-25 | Lokeshwar Vinata B | Hyaluronidase inhibitors as anti-cancer agents |
| AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| WO2009023047A2 (en) * | 2007-05-07 | 2009-02-19 | Peptimmune, Inc. | Methods for the directed expansion of epitopes for use as antibody ligands |
| EP2042516A1 (en) * | 2007-09-27 | 2009-04-01 | Protaffin Biotechnologie AG | Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same |
| EP2185719B1 (en) * | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
| EP2053060A1 (en) | 2007-10-24 | 2009-04-29 | Protaffin Biotechnologie AG | SDF-1-based glyocosaminoglycan antagonists and methods of using same |
| US8314212B2 (en) | 2008-02-08 | 2012-11-20 | Lindsey Miles | Plasminogen receptor PLG-RKT and antibodies thereof |
| JP2012516143A (ja) | 2009-01-30 | 2012-07-19 | プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト | グリコサミノグリカンを拮抗するｍｃｐ−１突然変異体およびその使用方法 |
| AU2010294225A1 (en) | 2009-09-11 | 2012-04-05 | Protaffin Biotechnologie Ag | Composition for treatment of CXCL8-mediated lung inflammation |
| CA2776513C (en) | 2009-11-24 | 2017-08-01 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| GB201012603D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| US20140073557A1 (en) | 2011-03-16 | 2014-03-13 | Protaffin Biotechnologie Ag | Fgfri-based antagonists with improved glycosaminoglycan affinity and methods of using same |
| EP2729487A2 (en) | 2011-07-08 | 2014-05-14 | Protaffin Biotechnologie AG | Novel sdf-1-based glycosaminoglycan antagonist and methods of using same |
| MX2014010164A (es) | 2012-02-22 | 2014-11-25 | Alethia Biotherapeutics Inc | Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer. |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| WO2014079957A1 (de) * | 2012-11-23 | 2014-05-30 | Bayer Cropscience Ag | Selektive inhibition der ethylensignaltransduktion |
| WO2014109519A1 (ko) * | 2013-01-10 | 2014-07-17 | 강원대학교산학협력단 | 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물 |
| US10047133B2 (en) | 2014-01-22 | 2018-08-14 | Antagonis Biotherapeutics Gmbh | Glycosaminoglycan-antagonising fusion proteins and methods of using same |
| EP4021927A1 (en) | 2019-08-29 | 2022-07-06 | Antagonis Biotherapeutics GmbH | T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity |
| CN110791523B (zh) * | 2019-12-13 | 2022-05-10 | 南京农业大学 | 一种棉花抗旱相关基因GhRCHY1及其应用 |
| KR20250040765A (ko) * | 2023-09-15 | 2025-03-25 | (주)케어젠 | 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4960691A (en) * | 1986-09-29 | 1990-10-02 | Abbott Laboratories | Chromatographic test strip for determining ligands or receptors |
| US5234911A (en) * | 1990-07-09 | 1993-08-10 | Gist-Brocades, N.V. | Substance with interleukin-8 inhibiting activity and process for its preparation |
| AU8947791A (en) | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
| EP0607777B1 (de) * | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Interleukin 8 |
| JP2694321B2 (ja) * | 1993-03-10 | 1997-12-24 | 大塚製薬株式会社 | インターロイキン−１阻害剤 |
| US5527546A (en) * | 1994-08-10 | 1996-06-18 | Bayer Corporation | Human interleukin 6 inhibitor |
| US5866402A (en) | 1995-05-05 | 1999-02-02 | Chiron Corporation | Chimeric MCP and DAF proteins with cell surface localizing domain |
| JPH1045602A (ja) * | 1996-07-31 | 1998-02-17 | Motoyasu Murakami | ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤 |
| US6852696B2 (en) * | 1999-03-26 | 2005-02-08 | The University Of Texas System | Inhibitors of glycosaminoglycans |
| ATE466069T1 (de) * | 2000-09-05 | 2010-05-15 | Biosight Ltd | Peptid-konjugierte antikrebs-prodrugs |
| UA77950C2 (en) * | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| GB0110430D0 (en) * | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| JP2003063980A (ja) * | 2001-08-28 | 2003-03-05 | Noevir Co Ltd | Ｒａｎｔｅｓ産生阻害剤 |
| US6982170B1 (en) * | 2001-12-17 | 2006-01-03 | Maine Medical Center Research Institute | Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 |
| JP2003306438A (ja) * | 2002-02-18 | 2003-10-28 | Shiseido Co Ltd | ケモカイン発現阻害剤 |
| JP2003267887A (ja) * | 2002-03-15 | 2003-09-25 | Shiseido Co Ltd | ケモカイン発現抑制皮膚外用剤 |
| IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| EP1495050A1 (en) * | 2002-04-10 | 2005-01-12 | Applied Research Systems ARS Holding N.V. | Novel antagonists of mcp proteins |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
-
2003
- 2003-12-04 AT AT0195203A patent/AT412785B/de not_active IP Right Cessation
-
2004
- 2004-12-02 CA CA002546789A patent/CA2546789A1/en not_active Abandoned
- 2004-12-02 KR KR1020067013411A patent/KR101188785B1/ko not_active Expired - Fee Related
- 2004-12-02 CN CN200480036160.6A patent/CN1890264B/zh not_active Expired - Fee Related
- 2004-12-02 ES ES06117339T patent/ES2330362T3/es not_active Expired - Lifetime
- 2004-12-02 SG SG200809009-4A patent/SG149000A1/en unknown
- 2004-12-02 PL PL06117339T patent/PL1752470T3/pl unknown
- 2004-12-02 EP EP10180909A patent/EP2311866A1/en not_active Withdrawn
- 2004-12-02 SI SI200431747T patent/SI1689775T1/sl unknown
- 2004-12-02 DK DK04801190.2T patent/DK1689775T3/da active
- 2004-12-02 PL PL04801190T patent/PL1689775T3/pl unknown
- 2004-12-02 EP EP10174625A patent/EP2363411A1/en not_active Withdrawn
- 2004-12-02 DE DE602004022595T patent/DE602004022595D1/de not_active Expired - Lifetime
- 2004-12-02 EP EP06117339A patent/EP1752470B1/en not_active Expired - Lifetime
- 2004-12-02 AU AU2004295104A patent/AU2004295104B2/en not_active Ceased
- 2004-12-02 AT AT06117339T patent/ATE439376T1/de active
- 2004-12-02 JP JP2006541888A patent/JP4980721B2/ja not_active Expired - Fee Related
- 2004-12-02 KR KR1020127011106A patent/KR101278459B1/ko not_active Expired - Fee Related
- 2004-12-02 ES ES04801190T patent/ES2369139T3/es not_active Expired - Lifetime
- 2004-12-02 PT PT06117339T patent/PT1752470E/pt unknown
- 2004-12-02 DK DK06117339T patent/DK1752470T3/da active
- 2004-12-02 EP EP10180974A patent/EP2270038A3/en not_active Withdrawn
- 2004-12-02 PT PT04801190T patent/PT1689775E/pt unknown
- 2004-12-02 WO PCT/EP2004/013670 patent/WO2005054285A1/en not_active Ceased
- 2004-12-02 BR BRPI0416544-6A patent/BRPI0416544A/pt not_active IP Right Cessation
- 2004-12-02 EP EP04801190A patent/EP1689775B1/en not_active Expired - Lifetime
- 2004-12-02 NZ NZ547612A patent/NZ547612A/en not_active IP Right Cessation
- 2004-12-02 AT AT04801190T patent/ATE515269T1/de active
- 2004-12-02 SI SI200431257T patent/SI1752470T1/sl unknown
-
2006
- 2006-05-11 IL IL175565A patent/IL175565A0/en unknown
- 2006-06-05 US US11/422,169 patent/US7585937B2/en not_active Expired - Fee Related
-
2008
- 2008-06-02 US US12/131,311 patent/US7807413B2/en not_active Expired - Fee Related
-
2009
- 2009-05-07 US US12/437,121 patent/US20110144305A1/en not_active Abandoned
- 2009-10-08 CY CY20091101039T patent/CY1109480T1/el unknown
-
2010
- 2010-08-18 US US12/858,456 patent/US20100331237A1/en not_active Abandoned
-
2011
- 2011-09-16 CY CY20111100904T patent/CY1112330T1/el unknown
-
2012
- 2012-02-27 JP JP2012040123A patent/JP2012139226A/ja active Pending
- 2012-04-05 JP JP2012086483A patent/JP2012165747A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
| CY1117551T1 (el) | Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου | |
| CY1114944T1 (el) | Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1116506T1 (el) | Αντισωματα εναντι masp-2 | |
| CY1119263T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων | |
| DE60238472D1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
| CY1105446T1 (el) | Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2 | |
| CY1108083T1 (el) | Αντιγονα και συνθεσεις του neisseria meningitidis | |
| ATE230487T1 (de) | Verfahren zur frühen diagnose von carcinomen | |
| ATE517922T1 (de) | Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
| CY1110295T1 (el) | Trans-9,10-δεϋδροεποθιλονη c και d, αναλογα αυτων και μεθοδοι παρασκευης | |
| ATE509120T1 (de) | Fusionsproteine zur detektion von analyten | |
| NO20016243D0 (no) | Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse | |
| EP1254267A4 (en) | COMPOSITIONS AND METHODS FOR PREVIOUS DIAGNOSIS OF OVARIAN CANCER | |
| UA84284C2 (ru) | Способы лечения, профилактики и диагностики инфекции helicobacter cerdo | |
| FR2827866B1 (fr) | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations | |
| BRPI0410861A (pt) | métodos e composições para a produção de aminoácidos | |
| CY1105452T1 (el) | Παραγωγα της κυκλοσπορινης και μεθοδος παρασκευης των εν λογω παραγωγων | |
| DE60335726D1 (de) | Chromoprotein und fluoroproteine | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| ATE365748T1 (de) | Polymer-konjugate von neublastin und methoden für deren verwendung | |
| EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks |